Vanda files NDA for tradipitant to treat motion sickness

Vanda Pharmaceuticals Inc.

Vanda disclosed via 8-K that it filed a New Drug Application for tradipitant for motion sickness.
Announcement made via social media post on X on January 25, 2025, referencing WWII context.
No approval or timeline provided; filing is a regulatory step toward potential commercialization.

item 7.01

Vanda Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-012740

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.